Related Experiment Videos
[Immunosuppression in Type I diabetes mellitus]
E J Schönle1, P C Sizonenko, G A Spinas
1Universitäts-Kinderklinik, Zürich.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
|October 9, 1990
Summary
The exact cause of type I diabetes remains unknown, but it is considered an autoimmune disease. Current immunosuppressive treatments show inefficiency and severe side effects, leading to recommendations against their use in newly diagnosed patients.
Area of Science:
- Immunology
- Endocrinology
- Pathogenesis of Diabetes Mellitus
Context:
- Type I diabetes, or insulin-dependent diabetes mellitus, is widely accepted to stem from an autoimmune process.
- The disease manifests after significant destruction (80-90%) of pancreatic insulin-producing beta cells.
- This understanding has prompted investigations into immune interventions, including the use of immunosuppressive drugs like cyclosporine A.
Purpose:
- To review the current understanding of type I diabetes etiopathogenesis.
- To evaluate the efficacy and safety of immunosuppressive therapies in type I diabetes.
- To provide recommendations regarding the use of immunosuppressive drugs in newly diagnosed type I diabetes patients.
Summary:
- The precise etiopathogenesis of type I diabetes is not fully elucidated but is recognized as an autoimmune condition.
- Immune intervention trials using immunosuppressants such as cyclosporine A are ongoing but remain experimental.
- Due to demonstrated inefficiency and significant adverse effects, the Swiss Diabetes Association advises against using these drugs in new type I diabetes cases.
Impact:
- Highlights the limitations of current immunosuppressive strategies for type I diabetes.
- Suggests a need for alternative or refined therapeutic approaches.
- Informs clinical practice guidelines for managing newly diagnosed type I diabetes.